125 related articles for article (PubMed ID: 22620489)
1. Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy.
Stoetzer OJ; Wittwer C; Lehner J; Fahmueller YN; Kohles N; Fersching DM; Leszinski G; Roessner J; Holdenrieder S
Expert Opin Biol Ther; 2012 Jun; 12 Suppl 1():S217-24. PubMed ID: 22620489
[TBL] [Abstract][Full Text] [Related]
2. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.
Wittwer C; Boeck S; Heinemann V; Haas M; Stieber P; Nagel D; Holdenrieder S
Int J Cancer; 2013 Dec; 133(11):2619-30. PubMed ID: 23729200
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of circulating nucleosomes in cancer.
Holdenrieder S; Nagel D; Schalhorn A; Heinemann V; Wilkowski R; von Pawel J; Raith H; Feldmann K; Kremer AE; Müller S; Geiger S; Hamann GF; Seidel D; Stieber P
Ann N Y Acad Sci; 2008 Aug; 1137():180-9. PubMed ID: 18837945
[TBL] [Abstract][Full Text] [Related]
4. The redox protein HMGB1 regulates cell death and survival in cancer treatment.
Tang D; Loze MT; Zeh HJ; Kang R
Autophagy; 2010 Nov; 6(8):1181-3. PubMed ID: 20861675
[TBL] [Abstract][Full Text] [Related]
5. Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagnosis.
Garrido MM; Ribeiro RM; Krüger K; Pinheiro LC; Guimarães JT; Holdenrieder S
In Vivo; 2021; 35(4):2207-2212. PubMed ID: 34182498
[TBL] [Abstract][Full Text] [Related]
6. Therapy control in oncology by circulating nucleosomes.
Holdenrieder S; Stieber P
Ann N Y Acad Sci; 2004 Jun; 1022():211-6. PubMed ID: 15251962
[TBL] [Abstract][Full Text] [Related]
7. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy.
Dong Xda E; Ito N; Lotze MT; Demarco RA; Popovic P; Shand SH; Watkins S; Winikoff S; Brown CK; Bartlett DL; Zeh HJ
J Immunother; 2007 Sep; 30(6):596-606. PubMed ID: 17667523
[TBL] [Abstract][Full Text] [Related]
8. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome.
Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Maeda S; Yamagishi S
Clin Biochem; 2011 Jun; 44(8-9):601-4. PubMed ID: 21211520
[TBL] [Abstract][Full Text] [Related]
9. Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance.
Trejo-Becerril C; Oñate-Ocaña LF; Taja-Chayeb L; Vanoye-Carlo A; Cetina L; Duenas-Gonzalez A
BMC Cancer; 2005 Jun; 5():65. PubMed ID: 15982417
[TBL] [Abstract][Full Text] [Related]
10. Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin.
Stoetzer OJ; Fersching DM; Salat C; Steinkohl O; Gabka CJ; Hamann U; Braun M; Feller AM; Heinemann V; Siegele B; Nagel D; Holdenrieder S
Cancer Lett; 2013 Aug; 336(1):140-8. PubMed ID: 23612068
[TBL] [Abstract][Full Text] [Related]
11. Apoptotic markers in cancer.
Holdenrieder S; Stieber P
Clin Biochem; 2004 Jul; 37(7):605-17. PubMed ID: 15234242
[TBL] [Abstract][Full Text] [Related]
12. Dealing with death: HMGB1 as a novel target for cancer therapy.
Lotze MT; DeMarco RA
Curr Opin Investig Drugs; 2003 Dec; 4(12):1405-9. PubMed ID: 14763124
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-products and circulating DNA in patients with acute pancreatitis.
Kocsis AK; Szabolcs A; Hofner P; Takács T; Farkas G; Boda K; Mándi Y
Pancreatology; 2009; 9(4):383-91. PubMed ID: 19451748
[TBL] [Abstract][Full Text] [Related]
14. Immunogenic death of colon cancer cells treated with oxaliplatin.
Tesniere A; Schlemmer F; Boige V; Kepp O; Martins I; Ghiringhelli F; Aymeric L; Michaud M; Apetoh L; Barault L; Mendiboure J; Pignon JP; Jooste V; van Endert P; Ducreux M; Zitvogel L; Piard F; Kroemer G
Oncogene; 2010 Jan; 29(4):482-91. PubMed ID: 19881547
[TBL] [Abstract][Full Text] [Related]
15. Circulating nucleosomes as a predictor of sepsis and organ dysfunction in critically ill patients.
Chen Q; Ye L; Jin Y; Zhang N; Lou T; Qiu Z; Jin Y; Cheng B; Fang X
Int J Infect Dis; 2012 Jul; 16(7):e558-64. PubMed ID: 22609014
[TBL] [Abstract][Full Text] [Related]
16. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy.
Kepp O; Galluzzi L; Martins I; Schlemmer F; Adjemian S; Michaud M; Sukkurwala AQ; Menger L; Zitvogel L; Kroemer G
Cancer Metastasis Rev; 2011 Mar; 30(1):61-9. PubMed ID: 21249425
[TBL] [Abstract][Full Text] [Related]
17. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer.
Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
Clin Lung Cancer; 2010 Jan; 11(1):36-44. PubMed ID: 20085866
[TBL] [Abstract][Full Text] [Related]
18. Circulating nucleosomes in serum.
Holdenrieder S; Stieber P; Bodenmüller H; Busch M; Von Pawel J; Schalhorn A; Nagel D; Seidel D
Ann N Y Acad Sci; 2001 Sep; 945():93-102. PubMed ID: 11708501
[TBL] [Abstract][Full Text] [Related]
19. High-mobility group box 1 represents a potential marker of disease activity and novel therapeutic target in systemic lupus erythematosus.
Urbonaviciute V; Voll RE
J Intern Med; 2011 Oct; 270(4):309-18. PubMed ID: 21793951
[TBL] [Abstract][Full Text] [Related]
20. Immunogenic Biomarkers HMGB1 and sRAGE Are Potential Diagnostic Tools for Ovarian Malignancies.
Schröder L; Rupp ABA; Gihr KME; Kobilay M; Domroese CM; Mallmann MR; Holdenrieder S
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
